IP University issues notice on Nurse Practitioner Critical Care Course For 2024-25 admissions, details

New Delhi- Guru Gobind Singh Indraprastha University (GGSIU) has started a new course named ‘Nurse Practitioner Critical Care’ for Nursing students for the academic session 2024-25, hence the University is inviting applications for admission forms. Along with this, through a notice, GGSIU has also explained the admission details and eligibility criteria of the course.

ADMISSION CRITERIA

Merit for admission will be based on interview (25% weightage to interview and 75% to marks obtained in the final qualifying examination).

Also Read: IP University Introduces Nurse Practitioner Critical Care Programme for Nursing Students, admissions open

ELIGIBILITY CRITERIA

i The candidate should be a Registered Nurse and Registered Midwife with any State Nursing Registration Council.

ii The Minimum education requirements shall be the passing of-

B.Sc. Nursing / B.Sc. (Hons.) Nursing / Post Basic B.Sc. Nursing/ M.Sc. Nursing with a minimum of 55% aggregate marks from an institution which is recognised by the Indian Nursing Council.

iii Minimum one year of work experience before or after Post B. Sc Nursing (preferably Critical care units).

iv Minimum one year of work experience after basic B.Sc. Nursing (preferably Critical Care units) is desirable.

All those candidates who fulfil the above-mentioned eligibility criteria for admission in the Nurse Practitioner Critical Care programme and are desirous to seek admission in the same are required to apply in a physical mode, in the prescribed format and submit their request during working days/hours at the Facilitation Centre of Guru Gobind Singh Indraprastha University, Sector 16C, Dwarka, New Delhi w.e.f. 22.04.2024 till 15.05.2024 along with the copies of relevant certificates (self-attested) along with a non-refundable Registration fee of Rs. 1500/- through Demand Draft drawn in favour of the Registrar, Guru Gobind Singh Indraprastha University, payable at Delhi.

The Nurse Practitioner Critical Care programme is a two-year program where the university offers 10 seats. The programme will be available at the Max Institute of Nursing Education and Training, Max Super Speciality Hospital, Saket.

To view the notice, click the link below

https://medicaldialogues.in/pdf_upload/ggsipucrdownload-236892.pdf

Powered by WPeMatico

Gandhi Medical College Bhopal Fixes 8-12 Duty Hours for Resident Doctors Amid Toxic Work Culture Allegations

Bhopal: Amid the pressure from the medical students to address the allegations of toxic work culture allegations at Gandhi Medical College, Bhopal, the institute has now finalized 8-12 duty hours and weekly off for the medical students.

Confirming this, the GMC Dean Kavita N Singh told FPJ, “Roster system has been finalised for residents and we have fixed 8 to 12 hours duty and weekly off for the students. It will ease pressure and develop a healthy work culture.”

The General Secretary of JUDA, Dr. Kuldeep Gupta also confirmed that “In a meeting of the college council, GMC dean has fixed duty hours to 8-12 for PG students. The junior doctors will also get weekly offs.”

Medical Dialogues had earlier reported that alleging a toxic work culture, 5 resident doctors of GMC Bhopal had threatened to commit mass suicide on 31st May 2024 if the authorities did not address their complaints. The doctors demanded the authorities to stop the non-stop working hours which they alleged sometimes get extended up to more than 24 hours and sometimes 36 hours. They urged the authorities to ensure a healthy working environment and to stop the toxicity and abuse.

Further, the PG medicos alleged being forced to work for more than 24-36 hours without sleep. They also claimed that they were not getting leave even for one day- even on Sundays. The doctors allegedly have to work even when they fall sick.

Also Read: Toxic Work Culture allegations rocks Gandhi Medical College Bhopal: 5 resident doctors threaten mass suicide

Apart from this, the resident doctors claimed in the letter that they have to face verbal abuse by seniors and consultants even after doing so much work. They alleged that they are being threatened as well of failing the exam and not receiving their degrees.

The doctors had flagged the issue of alleged toxic work culture in a letter directed to the Chairman of the Federation of All India Medical Association (FAIMA). Dr. Rohan Krishnan, the Chairman of FAIMA, had earlier informed that FAIMA had already formed a committee, headed by him, to address the issue. The association had appointed consultant psychiatrists and also discussed the matter with the leaders of the Junior Doctors’ Association of Madhya Pradesh and the Resident Doctors’ Association of GMC Bhopal. FAIMA also reached out to the dean of the institute, who had earlier assured to offer a positive solution regarding the issue.

As per the latest media report by Free Press Journal, the Dean of the institute has now finalised a 8-12 hours of duty roster system. However, the Daily added that the ‘Dean of the Institute and the medical college professors are at loggerheads’ over the fixation of 8-12 duty hours (roster system) for junior doctors.

Speaking to FPJ, the President of the Medical Teachers Association Dr. Rakesh Malviya pointed out that the training for the junior doctors is just like commando training.

He said, “Our medical training is to save the life of patients and not to discharge mere duty. This is the reason doctors are called next to God and we get so much respect in society. So 8 -12 hours duty hardly matters.”

“Junior doctors should accept this hard core fact that if they want to become full-fledged doctors (consultant), they should be mentally prepared just like commandos to save the life of patients. Anonymous letter does not serve the purpose. If any student has a problem, he or she should directly talk to us,” Dr. Malviya added.

Also Read: MBBS doctor preparing for NEET PG commits suicide

Powered by WPeMatico

193 kg US man undergoes total knee replacement at Jaslok Hospital

Mumbai: Jaslok Hospital achieves a remarkable milestone in the field of orthopaedic surgery with the successful Total Knee Replacement (TKR) procedure on a 193 kg patient, marking a significant breakthrough in addressing the challenges faced by overweight individuals seeking knee surgery.

Total Knee Replacement is a life-changing procedure for individuals suffering from debilitating knee pain, restoring mobility and enhancing their quality of life. However, overweight individuals often encounter barriers in accessing this treatment due to increased surgical risks and technical complexities.

Also Read:Jaslok Hospital unveils groundbreaking results in Parkinson’s disease management

The case of 72-year-old Mr. Richard Koszarek, weighing 193 kg patient admitted to Jaslok Hospital, exemplifies the dedication and innovation required to overcome these challenges. Dr Rajesh Nawalkar, Senior Consultant Orthopedics & renowned orthopaedic surgeon, led the multidisciplinary team, including Dr. Altaf Patel, Director General Medicine, Dr. Prerana Gomes, Additional Director Anaesthesiology and Dr. Dheemant Goleria, Consultant Plastic & Reconstructive Surgery in meticulously planning and executing the surgery.

One of the primary challenges in TKR for overweight patients is anaesthesia risk and the heightened potential for embolism. Additionally, the use of a tourniquet, a standard practice in TKR surgeries, poses technical difficulties due to the larger thigh circumference, increasing the risk of tissue damage and complications.

To address these concerns, Dr Nawalkar collaborated with instrument manufacturers to design specialized instruments tailored to the patient’s unique anatomy, ensuring optimal surgical outcomes. Moreover, extensive pre-operative evaluations and consultations were conducted to ensure patient readiness and informed consent.

The surgery, performed on January 7, 2024, was a testament to meticulous planning and expert execution, with no complications reported during the procedure. However, the journey to recovery was equally crucial, with rehabilitation playing a pivotal role in achieving successful outcomes.

Under the guidance of Dr. Stanley and the dedicated rehabilitation team, the patient received tailored care, including specialized aids for ambulation and ablution, facilitating a smoother recovery process. The support of Jaslok Hospital’s management and staff was instrumental in realizing this remarkable medical achievement.

Speaking about challenges in the surgery of such unique case Dr Rajesh Nawalkar, Senior Consultant Orthopaedics stated-“Every patient is different, and it’s crucial to adapt our surgical techniques to address their specific circumstances. By customizing our approach and collaborating closely with our colleagues, we were able to overcome the challenges posed by the patient’s weight and achieve a successful outcome.”

Adding to this Dr Prerana Gomes, Additional Director, Anaesthesiology said, “Managing anaesthesia for morbidly obese patients undergoing total knee replacement requires a comprehensive understanding of their physiological needs and potential risks. Our team approached this aspect of the surgery with utmost care, ensuring the patient’s safety and comfort throughout the procedure.”

Speaking about his life, Mr. Richard Koszarek mentioned, “Most of the doctors in India and overseas didn’t agree to perform surgery because of my over-weight, however with the guidance of Dr Altaf Patel and with the trained surgical skills of Dr Rajesh Nawalkar, I was finally operated and today I am back on feet.”

Dr Milind Khadke, Director Medical Services proudly mentioned “Today, as we celebrate this milestone, we also recognize the importance of perseverance, innovation, and collaboration in overcoming barriers to healthcare access. This case serves as an inspiration to individuals struggling with obesity-related knee issues, highlighting the possibility of achieving positive outcomes through specialized care and expertise”.

Also Read:8-year-old Yemeni boy undergoes rare thyroid cancer surgery at Jaslok Hospital

Powered by WPeMatico

ICMR-NIRRCH To Hold Workshop On Applications of Artificial Intelligence and Machine Learning in Disease Informatics, Details

New Delhi- The Indian Council of Medical Research (ICMR) and National Institute for Research in Reproductive and Child Health (NIRRCH) are going to organise a workshop on “Applications of Artificial Intelligence and Machine Learning in Disease Informatics” from 4th June 2024 to 7th June 2024. On this, ICMR-NIRRCH has issued an advertisement giving details on the workshop.

This workshop by the Biomedical Informatics Centre at ICMR-NIRRCH aims to provide a platform for enhancing skills to effectively manage extensive biological datasets using Artificial Intelligence and Machine Learning (AI/ML) through expert lectures in the field of disease informatics.

Also Read: JIPMER to hold Workshop on Mixed Methods Research in April, Details

HOW TO APPLY

Interested participants can enroll for the mentioned workshop through the link given in the advertisement. The workshop offers only 20 seats therefore, candidates are requested to register themselves as soon as possible on/before 30th April 2024. Following the registration, candidates will have to go through the selection process for the workshop which will be conducted on or before 5th May 2024. After the selection process, selected candidates will be informed later by email.

ELIGIBILITY

The minimum eligibility to participate in the workshop is that the candidate must be a postgraduate in Life Sciences. The candidate must have a prior knowledge of Python/R programming showcased either through publications or GitHub submissions.

Also Read: JIPMER to Host 10th Continuing Nursing Education Workshop Based on Short term course for Nurses, Details

TOPICS COVERED

Following are the topics that will be covered in the workshop-

1 Gaining in-depth biological insights from large-scale genomic data.

2 Use of Deep Learning in disease informatics.

3 Use of AI & ML to predict epigenetic signatures of various diseases.

4 Use of AI & ML in disease and risk prediction using voice features.

The workshop will take place on the 6th Floor, Dr. G. M. Phadke Memorial Library, ICMR-NIRRCH, Parel, Mumbai from 9:00 AM to 5:00 PM. The workshop is being funded by DHR-ICMR, however, no accommodation will be provided, therefore candidates are advised to make their own accommodations for the workshop.

To view the advertisement, click the link below

https://medicaldialogues.in/pdf_upload/aimlworkshopflyer-236702.pdf

Powered by WPeMatico

CDSCO Panel Grants Novartis Protocol Amendment Proposal For Ianalumab

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Novartis’ protocol amendment proposal for the drug Ianalumab (VAY736).

This came after Novartis presented protocol amendment version 03 dated 27 Apr 2023 and protocol amendment 04 dated 14 Dec 2023, protocol No. CVAY736I12301. The above study is a phase III, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAYHIT1).

This is a study of ianalumab (VAY736) in addition to first-line corticosteroids in patients with primary immune thrombocytopenia.

Ianalumab (VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus. This drug is being developed by Novartis. In 2021 ianalumab was undergoing Phase II/III trials.

Ianalumab is a fully human mAb that targets BAFF-R. It has a novel dual mechanism of action: blockade of BAFF-R-mediated signaling and potent depletion of B cells mediated by antibody-dependent cellular cytotoxicity.

At the recent SEC meeting for Hematology held on 18th April 2024, the expert panel reviewed protocol amendment version 03 dated 27 Apr 2023, and protocol amendment 04 dated 14 Dec 2023, protocol No. CVAY736I12301.

After detailed deliberation, the committee recommended the approval of protocol amendments as presented by the firm.

Also Read: Eli Lilly Gets CDSCO Panel Nod to Study Lepodisiran

Powered by WPeMatico

CDSCO panel rejects Pfizer Products India Local Clinical Trial Waiver Proposal for Elranatamab solution for injection

New Delhi: Reviewing the proposal presented by Pfizer Products India for grant of permission to import and market Elranatamab solution for injection 44 mg/1.1 mL (40 mg/mL) and 76 mg/1.9 mL(40 mg/mL), the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has rejected the firm’s request for waiver of the local clinical trial for grant of permission to import and market Elranatamab solution for injection.

This came after the drug maker Pfizer Products India presented the proposal for a grant of permission to import and market Elranatamab solution for injections 44 mg/1.1 mL (40 mg/mL) and 76 mg/1.9 mL(40 mg/mL) along with a request for a local clinical trial waiver.

The drug is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

The committee noted that the drug has an accelerated approval (conditional approval) in the USFDA for proposed indication based on Phase II clinical trial data and the trial is ongoing.

Elranatamab is a bispecific antibody used to treat adults with relapsed or refractory multiple myeloma.

Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure.

Elranatamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma. In the US, it is approved in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

At the recent SEC meeting for Oncology held on 3rd and 4th April 2024, the expert panel reviewed the proposal presented by the drug major Pfizer for granting permission to import and market Elranatamab solution for injection 44 mg/1.1 mL (40 mg/mL) and 76 mg/1.9 mL(40 mg/mL) along with the request for local clinical trial waiver.

After detailed deliberation, the committee did not consider the firm’s request for waiver of the local clinical trial for grant of permission to import and market Elranatamab solution for injection.

Also Read: CDSCO Panel Approves Eli Lilly’s protocol amendment proposal for Adjuvant Imlunestrant vs Standard Adjuvant study

Powered by WPeMatico

Why Did NEET PG 2024 Get Preponed? NMC responds to RTI

New Delhi: The National Eligibility-cum-Entrance Test Postgraduate Examination- NEET PG 2024 was preponed from 7th July 2024 to 23rd June 2024 due to the RathYatra festival, the National Medical Commission (NMC) revealed while responding to a Right to Information (RTI) application.

Filing the RTI application, social and political activist Dr Vivek Pandey sought the details of the meeting held to prepone the NEET PG 2024 exam. Dr. Pandey filed the RTI after receiving requests from the aspirants who were confused about the rationale behind such a decision to prepone the exam by around 15 days.

Responding to the RTI, the Postgraduate Medical Education Board (PGMEB) of NMC shared the minutes of the meeting dated 23.02.2024 when the Commission decided to prepone the exam. The meeting was held under the chairmanship of Dr. Vijay Oza, President of PGMEB on 21.02.2024 at 4:00 PM through virtual mode to discuss the examination and counselling schedule for NEET PG 2024 and the pattern of examination for NEET SS.

“Dr. Vinay Gupta informed that NEET PG-2024 which was initially planned to be held on 7th July 2024 has now been scheduled for 23rd June 2024 due to festival of RathYatra, falling on the 7th July, 2024,” stated the minutes of the meeting, a copy of which was shared by Dr. Pandey on X (formerly Twitter).

It further added that “Dr. B Srinivas shared the tentative Counselling schedule keeping in view the fact that cut off for completion of internship to become eligible for NEET PG-2024 is 15th Aug 2024.”

After detailed discussion, it was decided that the tentatively NEET PG 2024 would be conducted on 23rd June 2024 and its results would be declared on 15th July, 2024. As per the tentative schedule, the seat matrix would be finalised by NMC PG Board on 31st July 2024, counseling would be held between 5th August 2024 to 15th October 2024, and the academic session would start on 16th September 2024.

Commenting on the matter, Dr. Pandey told Medical Dialogues, “As an organization committed to ensuring fairness and accessibility for all candidates, the decision by the National Medical Commission to reschedule the examination date due to the Rathayatra festival is a commendable step. Acknowledging the potential challenges students may face regarding transportation on such a significant day, the NMC’s decision reflects sensitivity to the needs of aspirants.”

“However, it would be more helpful for aspirants if NMC to consider shifting the examination date to a period between 8th to 15th July. Rather than preponing it to 23 June,” he further added.

Also Read: Why Did NEET PG 2024 Get Preponed? RTI Filed Before NMC

Medical Dialogues had earlier reported that the aspirants of the NEET PG 2024 examination were upset with the NMC notice dated 20.03.2024 through which the Commission preponed the NEET PG 2024 exam date from 7th July to 23rd June.

Taking to social media platforms, the aspirants started questioning the logic behind such a decision taken by the authorities, while some of the users and experts expressed their concern about the impact of preponement on the students preparing for the exam.

Referring to the notice dated 20.03.2024, Dr. Pandey mentioned in the RTI application, “Kindly provide the details of minute of the meeting held to preponed the NEET PG 2024 exam. please provide the information of suggestions given to preponed NEET PG 2024 exam.”

Addressing the issue, Dr. Pandey mentioned in an X post, “We must know why exam is Pre-Poned, if result is coming late, counselling is late, then what is benefit of conducting exam 15 days before previous date ?”

The schedule for NEET PG 2024 has been changed a couple of times since last year. Earlier, releasing the tentative schedule of exams, NBE had last year announced that the NEET PG 2024 would tentatively be conducted on 3rd March 2024. Thereafter, media reports started speculating that the exam would be held in the first week of July.

Also Read:Breaking News: NMC reschedules NEET PG 2024, here are important dates

Confirming such speculations, NBE, the authority in charge of conducting the exam then announced that NEET PG 2024 would be conducted on July 07, 2024, and the cut-off date for eligibility to appear in the NEET-PG 2024 shall be 15th August 2024.

However, recently while preponing the exam, the National Medical Commission (NMC) declared that the NEET PG 2024 exam would be held on June 23, 2024. On the cut-off date for eligibility to appear in the NEET PG 2024, the NMC stated, “It has also been decided that the cut off date for completion of internship to become eligible for NEET PG-2024 is 15th Aug 2024.”

Also Read: NEET PG aspirants upset with NMC decision to prepone exam

Powered by WPeMatico

Medtronic gets USFDA approval for Inceptiv closed-loop spinal cord stimulator for chronic pain

Dublin: Medtronic plc, a global leader in healthcare technology, has announced that the U.S. Food and Drug Administration (FDA) has approved the Inceptiv closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain. Inceptiv is the Medtronic SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time, keeping therapy in harmony with the motions of daily life.

“Pain is intensely personal, and stimulation therapy should meet the needs of every patient, moment to moment,” said Dr. Krishnan Chakravarthy, M.D., Ph.D., Director of Innovative Pain Treatment Solutions and Surgery Center, VA San Diego Healthcare, and Chairman of the Empower You Chronic Pain Foundation. “Inceptiv listens to what the body is saying and, more quickly than you can blink, it seamlessly adjusts. This represents an important leap forward for the treatment of chronic pain.”

Traditional fixed-output SCS devices deliver constant, mild electrical impulses that disrupt pain signals before they reach the brain. As patients go about their daily lives, certain movements such as laughing, bending, or sneezing may result in brief moments of uncomfortable overstimulation. This in turn may lead some patients to turn down their device’s stimulation output, resulting in a suboptimal therapy experience.

By contrast, Inceptiv SCS senses biological signals and consistently maintains the physician’s prescribed stimulation that is tailored to a patient’s needs. Specialized circuitry and a proprietary algorithm detect ECAPs (Evoked Compound Action Potentials), signals generated by the spinal cord in response to electrical stimuli. ECAPs are a direct measure of how much nerve tissue is activated in the spinal cord and can be used to inform real-time adjustments to stimulation. Inceptiv SCS senses the body’s response to stimulation† 50 times per second and instantly increases or decreases stimulation to maintain prescribed settings as determined by the physician.

The Inceptiv system delivers additional advantages beyond its closed-loop capability. Inceptiv offers unparalleled access to diagnostic imaging, with 1.5T and 3T full-body MRI access with no power or impedance restrictions.‡ It is the only FDA-approved closed-loop spinal cord stimulator that offers full-body 3T MRI access. Up to 84% of SCS-implanted patients are expected to need at least one MRI within five years of implant. It is the world’s smallest and thinnest fully implantable SCS device, designed for patient comfort. In addition, Inceptiv SCS allows the option of multiple types of waveforms, including Medtronic’s proprietary DTM SCS therapy, which demonstrated an 84% responder rate at 12 months in a large, multicenter randomized controlled trial (RCT). Patients with Inceptiv SCS can also access CareGuidePro, a mobile application and web portal that serves as a virtual guide throughout their Medtronic spinal cord stimulation therapy journey.

“A new era for spinal cord stimulation technology is beginning, and with Inceptiv SCS, Medtronic is at the forefront,” said David Carr, vice president and general manager, Pain Interventions within the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic. “For patients dealing with chronic pain, every day is a struggle. They deserve personalized and effective relief, without compromising future access to MRI. They deserve the comfort that the smallest and thinnest device on the market can provide. We are proud to offer the most cutting-edge solution available today with Inceptiv SCS.”

Medtronic will initiate the U.S. market launch of Inceptiv in the coming weeks. The system previously earned approvals for sale in Europe and in Japan.

Read also: Medtronic inaugurates RnD center outside US in Hyderabad

Powered by WPeMatico

No approvals if failed to submit Self-Assessment forms, Compliance reports by April 30th: NMC issues warning to medical colleges

Noting that some of the medical colleges have not submitted the requisite documents within the prescribed timeline, the Medical Assessment and Rating Board (MARB) of the National Medical Commission (NMC) has warned that the Compliance report and the Self Assessment Forms (SAF) for both MBBS and PG courses shall not be processed for the Academic Year 2024-2025 if they are received after 30th April 2024.

The Apex Medical Commission has warned all the medical colleges across the country that applications for UG and PG medical courses shall be liable to be disapproved without any further communication if the documents are received after 30.04.2024.
For more information click on the link below:
No Approvals If Failed To Submit Self-Assessment Forms, Compliance Reports By April 30th: NMC Warns Medical Colleges

Powered by WPeMatico

Health Bulletin 27/ April/ 2024

Here are the top heath stories for the day:

NMC initiates online survey on mental health, medical colleges told to submit response by 3rd May, 2024
The National Task Force, constituted by the National Medical Commission (NMC) is conducting an online survey on the mental health and well-being of medical students.
Through a recent notice, the Apex Medical Commission has shared a link to the Google form in this regard and asked all medical students and faculties of medical colleges to submit their responses by 3rd May 2024.
For more information, click on the link below:
NMC Initiates Online Survey On Mental Health, Seeks Response From MBBS, PG Medicos, Faculties

Bengaluru Radiologist assaulted, robbed of Rs 50 lakh gold, cash at gunpoint
A radiologist’s house in the city became the scene of a major money heist after three miscreants entered his house, assaulted him, threatened him at gunpoint and robbed 500 grams of gold ornaments worth Rs 30 lakh, Rs 20 lakh in cash, and six wristwatches.
In response to the robbery, the police registered a case against the three individuals under relevant sections of the Indian Penal Code (IPC). They suspect the miscreants to be gangsters from Uttar Pradesh who planned the robbery meticulously after observing the doctor’s family members’ routines. Consequently, they formed a special investigation team to catch the culprits.
For more information, click on the link below:

Rise in diabetics forced to go for amputations due to foot ulcers: CMC Vellore Study
A recent study conducted by the Christian Medical College, Vellore, has uncovered a concerning trend among diabetes patients in India: a rising number of toe and foot amputations due to diabetes-related sores. Published in the peer-reviewed journal Science Direct, the study reveals that the risk of subsequent amputations triples after the first procedure, underscoring the severity of the issue.
In India, diabetic foot ulcers (DFU) tend to present as larger wounds compared to global standards, leading to higher rates of amputation. The study, led by the Department of Endocrinology, Diabetes, and Metabolism at Christian Medical College, Vellore, found that over a 10-year period, mortality rates among patients with DFU range between 25% and 30%, with heart-related issues and sepsis infections being the primary causes of death.
NCDRC slaps Rs 25 lakh compensation on Safdarjung hospital, 2 cardiologists
The National Consumer Disputes Redressal Commission (NCDRC) recently upheld the Delhi State Consumer Court’s order to hold Safdarjung Hospital and its two Cardiologists liable for medical negligence and directed them to pay Rs 25 lakh compensation to the wife of the patient, who died during the treatment.
In its order, the NCDRC held, “the standard of care and medical protocol required the administering of Inj. Nirmin which was not available in the Hospital. The State Commission’s finding that this amounted to negligence is based on its view that an essential injection such as this was to have been available in a hospital such as the appellant hospital. There is no evidence led to prove that the alternative of Inj. Albumin was the alternative prescribed under the protocol for treatment. No medical records as mandated under the Medical Council of India Regulations (MCI) 2002 were also made available.”
For more information, click on the link below:

Powered by WPeMatico